STK11 mutant
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene STK11
Variant mutant
Impact List unknown
Protein Effect unknown
Gene Variant Descriptions STK11 mutant indicates an unspecified mutation in the STK11 gene.
Associated Drug Resistance
Category Variants Paths

STK11 mutant

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04774952 Phase I RMC-5552 Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors Completed USA 0
NCT04512430 Phase II Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients Terminated ESP 0
NCT02352844 Phase II Everolimus Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations Completed USA 0
NCT06495125 Phase II Defactinib + Nivolumab + RO5126766 Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer Recruiting USA 0
NCT04776447 Phase II Atezolizumab + Carboplatin + Paclitaxel Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (APOLO) Active, not recruiting ESP 0
NCT07247786 Phase II Carboplatin + Durvalumab + Paclitaxel Carboplatin + Durvalumab + Fecal microbiota + Paclitaxel Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) (MIGRANT) Not yet recruiting ESP 0
NCT04916236 Phase I LY3214996 + RMC-4630 Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers (SHERPA) Terminated NLD 0
NCT06120075 Phase I AB801 AB801 + Docetaxel AB801 + Docetaxel + Zimberelimab A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27) Recruiting USA 0
NCT04564157 Phase III Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT) Active, not recruiting ESP 0
NCT05807048 Phase II Daratumumab and hyaluronidase-fihj Daratumumab in STK11 Mutated NSCLC Recruiting USA 0
NCT04471415 Phase Ib/II DRP-104 Atezolizumab + DRP-104 Study to Investigate DRP-104 in Adults With Advanced Solid Tumors Terminated USA | ESP | DEU 2
NCT03375307 Phase II Olaparib Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes Recruiting USA 0
NCT06008093 Phase III Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium + Tremelimumab A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON) Recruiting USA 0
NCT06188208 Phase I Pembrolizumab + VVD-130850 VVD-130850 A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors Active, not recruiting USA | ESP | AUS 0
NCT05704634 Phase I Cemiplimab + Sarilumab A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. Active, not recruiting USA 0
NCT03872427 Phase II Telaglenastat Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study Active, not recruiting USA 0
NCT07017829 Phase II GT103 + Pembrolizumab GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer Recruiting USA 0
NCT07207395 Phase II JBI-802 JBI-802 + Pembrolizumab A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation. Recruiting USA 0
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT05469178 Phase Ib/II Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium A Clinical Study of Bemcentinib with Standard of Care Chemoimmunotherapy in Untreated Advanced/metastatic Non-small Cell Lung Cancer Patients with a Mutation in the STK11 Gene Terminated USA | POL | ITA | HUN | GRC | FRA | ESP 0
NCT05887492 Phase Ib/II Pembrolizumab + TNG260 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors Recruiting USA 0
NCT07153445 Phase II Atezolizumab + Carboplatin + Paclitaxel Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) (ATHENEA) Recruiting ESP 0
NCT02646319 Phase I Nab-rapamycin Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Completed USA 0
NCT06431633 Phase II Zimberelimab Cisplatin Sacituzumab govitecan-hziy + Zimberelimab Carboplatin Study of Treatment with Sacituzumab and Zimberelimab for Patients with Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (ARIAN) Recruiting ESP 0
NCT05445843 Phase II JDQ443 Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression >= 1% and an STK11 Co-mutation. Active, not recruiting USA | TUR | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | BRA | BEL | AUT | ARG 5